<p>Voss Capital, LP, along with Voss Value Master Fund, LP, Voss Value-Oriented Special Situations Fund, LP, Voss Advisors GP, LLC, and Travis W. Cocke, reported the acquisition of common shares of Rein Therapeutics Inc. as beneficial owners. Other reporting beneficial owners were also included in the filing. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921895-25-003156), on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

RNTX

<p>Voss Capital, LP, and associated entities reported the acquisition of common shares of Rein Therapeutics Inc. as beneficial owners. The filing includes other beneficial owners and can be accessed via EDGAR. This AI-generated news brief is for informational purposes only and not financial advice.</p>

Voss Capital Reports Acquisition of Rein Therapeutics Common Shares